Quantum BioPharma Ltd. Cash Flows From Used In Financing Activities
Quantum BioPharma Ltd. (QNTM) reported Cash Flows From Used In Financing Activities of $6.10 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Cash Flow › Financing Activities
ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2026-03-26
CAD
| Period end | Cash Flows From Used In Financing Activities 12 month |
|---|---|
| 2019-12-31 | 5.33M CAD 40-F/A · filed 2020-03-17 |
| 2018-12-31 | 44.88M CAD 40-F/A · filed 2020-03-17 |
USD
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 9 month | Cash Flows From Used In Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.41M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $1.68M derived: sum of 2 quarters · filed 2026-03-26 | $2.97M derived: sum of 3 quarters · filed 2026-03-26 | $6.10M 20-F · filed 2026-03-26 |
| 2025-09-30 | $261.43K derived: 6-K 9 month − 6-K 6 month · filed 2025-11-06 | $1.55M derived: sum of 2 quarters · filed 2025-11-06 | $4.68M 6-K · filed 2025-11-06 | $7.15M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $1.29M derived: 6-K 6 month − 6-K/A 3 month · filed 2025-08-07 | $4.42M 6-K · filed 2025-08-07 | $6.89M derived: sum of 3 quarters · filed 2026-03-26 | $13.63M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $3.13M 6-K/A · filed 2025-06-16 | $5.60M derived: sum of 2 quarters · filed 2026-03-26 | $12.34M derived: sum of 3 quarters · filed 2026-03-26 | $14.18M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $2.47M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $9.21M derived: sum of 2 quarters · filed 2026-03-26 | $11.05M derived: sum of 3 quarters · filed 2026-03-26 | $11.62M 20-F · filed 2026-03-26 |
| 2024-09-30 | $6.74M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-06 | $8.58M derived: sum of 2 quarters · filed 2025-11-06 | $9.15M 6-K · filed 2025-11-06 | $9.13M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $1.84M derived: 6-K 6 month − 6-K/A 3 month · filed 2025-08-07 | $2.41M 6-K · filed 2025-08-07 | $2.39M derived: sum of 3 quarters · filed 2026-03-26 | $2.33M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $568.72K 6-K/A · filed 2025-06-16 | $543.50K derived: sum of 2 quarters · filed 2026-03-26 | $488.73K derived: sum of 3 quarters · filed 2026-03-26 | |
| 2023-12-31 | -$25.22K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$79.99K derived: sum of 2 quarters · filed 2026-03-26 | -$3.13M 20-F · filed 2026-03-26 | |
| 2023-09-30 | -$54.78K derived: 6-K 9 month − 6-K/A 6 month · filed 2024-11-12 | -$3.10M 6-K · filed 2024-11-12 | ||
| 2023-06-30 | -$3.05M 6-K/A · filed 2024-08-19 | |||
| 2022-12-31 | -$2.07M 20-F/A · filed 2025-03-31 | |||
| 2021-12-31 | $38.21M 20-F · filed 2024-04-02 | |||
| 2020-12-31 | $24.17M 20-F · filed 2023-03-31 | |||
| 2019-12-31 | $4.01M 40-F · filed 2021-03-17 |